News

Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer

CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers…

8 months ago

Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France

-- Reimbursed early access program allows for patients with hypothalamic obesity in France to receive setmelanotide treatment ---- Early access…

8 months ago

22nd Century Group (Nasdaq: XXII) to Announce Second Quarter 2023 Results on August 14, 2023

BUFFALO, N.Y., Aug. 07, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to…

8 months ago

PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care

Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platformsMENLO PARK, Calif. and STAMFORD,…

8 months ago

OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering

Single nucleotide polymorphism (SNP) analysis module and interpretation of plasmids now availableAdded reporting customized for the needs of hospital epidemiologists…

8 months ago

Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming ANAVEX®3-71 Clinical Cardiovascular Safety

NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage…

8 months ago

Collegium Announces $50 Million Accelerated Share Repurchase Program

STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed…

8 months ago

Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Preclinical data with APG777 demonstrate the potential for significantly improved dosing over standard of care, including the potential for every…

8 months ago

Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer

SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on…

8 months ago

Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights

Reported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis (GM1); PBGM01 continued to have…

8 months ago